Rpl24Bst mutation suppresses colorectal cancer by promoting eEF2 phosphorylation via eEF2K

John R. P. Knight, Nikola Vlahov, David M. Gay, Rachel A. Ridgway, William J. Faller, Christopher G Proud, Giovanna R. Mallucci, Tobias von der Haar, C. Mark Smales, Anne E. Willis, Owen J. Sansom

Research output: Working paperPreprint


Increased protein synthesis supports the rapid proliferation associated with cancer. The Rpl24Bst mutant mouse reduces the expression of the ribosomal protein RPL24 and has been used to suppress translation and limit tumorigenesis in multiple mouse models of cancer. Here we show that Rpl24Bst also suppresses tumorigenesis and proliferation in a model of colorectal cancer with two common patient mutations, Apc and Kras. In contrast to previous reports, Rpl24Bst mutation has no effect on ribosomal subunit abundance but suppresses translation elongation through phosphorylation of eEF2, reducing protein synthesis by 40% in tumour cells. Ablating eEF2 phosphorylation in Rpl24Bst mutant mice by inactivating its kinase, eEF2K, completely restores the rates of elongation and protein synthesis. Furthermore, eEF2K activity is required for the Rpl24Bst mutant to suppress tumorigenesis. This work demonstrates that elevation of eEF2 phosphorylation is an effective means to suppress colorectal tumorigenesis with two driver mutations. This positions translation elongation as a therapeutic target in colorectal cancer, as well as other cancers where the Rpl24Bst mutation has a tumour suppressive effect in mouse models.
Original languageEnglish
Number of pages57
Publication statusPublished - 5 May 2021

Publication series

NameCOVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Rpl24Bst mutation suppresses colorectal cancer by promoting eEF2 phosphorylation via eEF2K'. Together they form a unique fingerprint.

Cite this